Literature DB >> 30587420

Intracerebral hemorrhage associated with warfarin versus non-vitamin K antagonist oral anticoagulants in Asian patients.

Ho Geol Woo1, Inyoung Chung2, Dong Seok Gwak2, Baik Kyun Kim3, Ji Hoon Kang4, Beom Joon Kim4, Hee-Joon Bae4, Moon-Ku Han5.   

Abstract

Non-valvular atrial fibrillation patients receiving non-vitamin K antagonist oral anticoagulants (NOACs) have half the incidence of intracerebral hemorrhage (ICH) compared to those receiving warfarin. However, the differences in outcomes of NOAC-associated ICH (NICH) and warfarin-associated ICH (WICH) remain controversial. In this study, we investigated the clinical outcome and radiologic findings of ICH in Asian patients receiving NOACs or warfarin. We retrospectively reviewed the medical records of 544 ICH patients admitted to our hospital from January 2013 through December 2017, and compared the baseline demographics, clinical characteristics, ICH-related radiologic findings, and clinical outcome between the WICH and NICH groups. WICH and NICH were diagnosed in 46 and 13 patients, respectively. Lesions were located more frequently in the supratentorial deep area (45.7% and 46.2%) than the lobar area (30.4% and 30.8%) or brainstem and cerebellum (23.9% and 23.1%) in the WICH and NICH groups, respectively. The hematoma expansion and concomitant intraventricular hemorrhage (IVH) rate was significantly higher in the WICH group than in the NICH group (58.7% versus 7.7%, P = 0.001 and 50.0% versus 15.4%, P = 0.030, respectively). Hematoma expansion (odds ratio [OR]: 50.546; 95% confidence interval [CI]: 2.763-924.748; P = 0.008) and concomitant IVH (OR: 9.240; 95% CI: 1.450-58.892; P = 0.019) were independently associated with mortality at three months, after adjustment for confounding variables. Our results indicate that the radiological findings and clinical outcome at three months in patients with ICH are more favorable in those receiving NOAC therapy than in those receiving warfarin treatment.
Copyright © 2018. Published by Elsevier Ltd.

Entities:  

Keywords:  Anticoagulants; Atrial fibrillation; Cerebral hemorrhage; Warfarin

Mesh:

Substances:

Year:  2018        PMID: 30587420     DOI: 10.1016/j.jocn.2018.10.102

Source DB:  PubMed          Journal:  J Clin Neurosci        ISSN: 0967-5868            Impact factor:   1.961


  5 in total

1.  Cytokines, miRNAs, and Antioxidants as Combined Non-invasive Biomarkers for Parkinson's Disease.

Authors:  Amr Ghit; Hany El Deeb
Journal:  J Mol Neurosci       Date:  2022-02-23       Impact factor: 3.444

Review 2.  Systematic review and meta-analysis of Sniffin Sticks Test performance in Parkinson's disease patients in different countries.

Authors:  Sheila Trentin; Bruno Samuel Fraiman de Oliveira; Yuri Ferreira Felloni Borges; Carlos Roberto de Mello Rieder
Journal:  Eur Arch Otorhinolaryngol       Date:  2021-07-28       Impact factor: 2.503

Review 3.  Indirect comparison of novel Oral anticoagulants among Asians with non-Valvular atrial fibrillation in the real world setting: a network meta-analysis.

Authors:  Jianchao Zhang; Junnan Tang; Xiaolin Cui; Bo Wang; Mengsen Bu; Yan Bai; Kai Wang; Jiacheng Guo; Deliang Shen; Jinying Zhang
Journal:  BMC Cardiovasc Disord       Date:  2019-07-31       Impact factor: 2.298

4.  Rivaroxaban-associated intracranial hemorrhage in Saudi atrial fibrillation patients.

Authors:  Amal Alkhotani; Nouf Alrishi; Meshari Alharthi; Waleed Alzahrani
Journal:  Medicine (Baltimore)       Date:  2020-11-25       Impact factor: 1.889

5.  Clinical Characteristics and Outcomes Associated With Oral Anticoagulant Use Among Patients Hospitalized With Intracerebral Hemorrhage.

Authors:  Ying Xian; Shuaiqi Zhang; Taku Inohara; Maria Grau-Sepulveda; Roland A Matsouaka; Eric D Peterson; Jonathan P Piccini; Eric E Smith; Kevin N Sheth; Deepak L Bhatt; Gregg C Fonarow; Lee H Schwamm
Journal:  JAMA Netw Open       Date:  2021-02-01
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.